AlphAIAlphAI — Financial news for AI agents
timothysykes.comSEP 173 min read$TEM

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

Original reporting
timothysykes.com
Published Sep 17, 2026, 4:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 5:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite — source image
Source · timothysykes.com
Decision brief

The 30-second read

$TEMBullishMed
01

Why it matters

The earnings release turned the company profitable and sparked a 14% intraday rally, suggesting short‑term trading opportunities.

02

Market read

First‑time profitability and strong revenue growth in AI‑healthcare sector drive notable price movement, making the story highly relevant for traders.

03

What to watch

High leverage ($1.36B debt) and integration risk of the Personalis deal could limit upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Timothy Sykes' outlet provides a momentum‑focused recap of Tempus AI's Q2 earnings and price action.

Company-level read

Ticker impact

$TEMBullishHigh confidence
Context

Q2 2026 report shows revenue up 22% to $382.5M, first positive net income of $5.6M and EBITDA of $45M, driving a 14.38% price jump.

Expected impact

Expect continued short‑term upside if momentum holds, with potential pull‑back buying opportunities.

Evidence & confidence

The combination of double‑digit revenue growth, margin expansion and first‑time profitability is rare for a micro‑cap AI‑health firm and has already moved the stock sharply.

Market effects

Sector

Highlights growing investor appetite for AI‑enabled healthcare platforms.

Regional

U.S. biotech and AI sectors may see increased buying pressure.

Global

Signals broader trend of AI integration in life‑sciences worldwide.

Counterpoint

What could challenge this read

The stock may be overbought after a rapid rally; execution risk on the Personalis acquisition could pressure the price.

Key entities

  • company
    Tempus AI Inc.

    AI‑driven healthcare data and diagnostics firm.

  • company
    Personalis

    Target acquisition to expand AI‑driven drug discovery capabilities.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 17
$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min
SEP 15
$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min
SEP 5
$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min
SEP 2
$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min